Early Adherence to Immunomodulators in Multiple Myeloma: Retrospective Observations from a Safety-Net Hospital
Current Oncology · 19.07.2026 · 33 (7) · 432
DOI: 10.3390/curroncol33070432 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 19.07.2026. Verfasst von Onyebuchi Ononogbu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, Houston, TX 77204, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunomodulating Agents, Immunologic Factors. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Multiple myeloma (MM) disproportionately affects older adults and racial/ethnic minorities, many of whom face socioeconomic barriers to care. Immunomodulators (IMiDs) are central to MM therapy, but their benefit relies on timely initiation and sustained adherence. In safety-net settings, barriers such as insurance approvals, Patient Medication Assistance Program (PMAP) enrollment, and Risk Evaluation and Mitigation Strategy (REMS) requirements may influence adherence. This study evaluated IMiD adherence during the first two years of therapy among socioeconomically vulnerable MM patients in a large safety-net hospital, with attention to PMAP enrollment and treatment delays.
Methods
We conducted a retrospective cohort study of adults (≥18 years) with newly diagnosed MM between October 2010 and January 2022 who initiated lenalidomide or pomalidomide at a safety-net hospital. Adherence was measured using the proportion of days covered (PDC). Delays in initiation were defined as ≥1 month from diagnosis to first IMiD prescription fill. This threshold was selected a priori based on the REMS-mandated 28-day prescription supply limit for lenalidomide and pomalidomide, which establishes a natural monthly treatment cycle; a delay exceeding one full 28-day cycle before therapy initiation is operationally meaningful within the REMS framework.
Results
Eighty patients met criteria (mean age 55.1 years; 56.3% Hispanic/Latino; 31.3% African American). Most were unemployed (63.8%), 42.5% uninsured, and 57.5% enrolled in PMAP. Only 12.5% achieved PDC ≥ 80%. Median PDC was higher among PMAP enrollees (0.40 vs. 0.31; p = 0.0293) and transplant-ineligible patients (0.46 vs. 0.27; p = 0.0218). Delays ≥ 1 month occurred in 65% of patients.
Conclusions
Adherence to IMiDs was suboptimal in this younger safety-net cohort. Although PMAP improved adherence, program delays may reduce early treatment benefits, underscoring the need for streamlined access and targeted interventions to address both patient- and system-level barriers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, Houston, TX 77204, USA.
- Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX 77204, USA.
- Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Lyndon B. Johonson Outpatient Hematology, Harris Health System, Houston, TX 77030, USA.
- Department of Medical Oncology, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates.
- McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
ORCID-Profile: Onyebuchi Ononogbu, Javeria Khalid, Yaser Alkhatib
Zitieren
APA
Ononogbu, O., Mohr, S., Khalid, J., Glass, A., Emovon, J., Ma, H., Alkhatib, Y., & Correa, A. (2026). Early Adherence to Immunomodulators in Multiple Myeloma: Retrospective Observations from a Safety-Net Hospital. Current Oncology, 33(7), 432. https://doi.org/10.3390/curroncol33070432
Vancouver
Ononogbu O, Mohr S, Khalid J, Glass A, Emovon J, Ma H, et al. Early Adherence to Immunomodulators in Multiple Myeloma: Retrospective Observations from a Safety-Net Hospital. Current Oncology. 2026;33(7):432. doi:10.3390/curroncol33070432
BibTeX
@article{Ononogbu2026,
author = {Ononogbu, Onyebuchi and Mohr, Sydney and Khalid, Javeria and Glass, Alyssa and Emovon, Jane and Ma, Hilary and Alkhatib, Yaser and Correa, Amit},
title = {Early Adherence to Immunomodulators in Multiple Myeloma: Retrospective Observations from a Safety-Net Hospital},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {7},
pages = {432},
doi = {10.3390/curroncol33070432}
}
EUVIMED